Company Profile

Opiant Pharmaceuticals, Inc., is a specialty pharmaceutical company developing medicines for addictions and drug overdose. The Company has developed NARCAN (naloxone hydrochloride) Nasal Spray, a treatment to reverse opioid overdose. Its lead development product include OPNT003. The Company's pipeline includes medicines in development for Opioid Overdose Reversal (OOR), Alcohol Use Disorder (AUD), Opioid Use Disorder (OUD), and Acute Cannabinoid Overdose (ACO). The Company also is focused on other treatment opportunities within the addiction and drug overdose field.

Employees

Sector

Biotechnology & Medical Research

More about the company

23-03-02	Indivior completes acquisition of Opiant Pharmaceuticals	AN
23-03-02	Indivior Wraps Up Deal to Buy Opiant Pharmaceuticals	MT

23-03-02	Indivior completes acquisition of Opiant Pharmaceuticals	AN
23-03-02	Indivior Wraps Up Deal to Buy Opiant Pharmaceuticals	MT
23-03-02	Opiant Pharmaceuticals, Inc.(NasdaqCM:OPNT) dropped from NASDAQ Composite Index	CI
23-03-02	Opiant Pharmaceuticals, Inc.(NasdaqCM:OPNT) dropped from S&P TMI Index	CI
23-03-01	Indivior PLC completed the acquisition of Opiant Pharmaceuticals, Inc. from a group of shareholders.	CI
23-03-01	Opiant Pharmaceuticals, Inc. - Shareholder/Analyst Call
23-02-07	Indivior Wins US Regulatory Nod To Acquire Opiant Pharmaceuticals	MT
23-02-06	Indivior announces expiry of waiting period for Opiant purchase	AN
23-02-06	Opiant Pharmaceuticals Says Waiting Period Expires for Proposed Takeover by Indivior Expires	MT
23-02-06	Indivior Nears Acquisition of Opiant Pharmaceuticals	MT
23-01-26	Warren tells FTC she is "particularly concerned" about Amgen and Indivior deals	RE
23-01-20	Opiant Pharmaceuticals Granted FDA Priority Review for Opioid Overdose Therapy	MT
23-01-19	Opiant Pharmaceuticals Announces FDA Acceptance and Priority Review of NDA for OPNT003, Nasal Nalmefene, for Opioid Overdose	CI

23-03-02	OPIANT PHARMACEUTICALS, INC. : Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits (form 8-K)	AQ
23-03-01	OPIANT PHARMACEUTICALS, INC. : Submission of Matters to a Vote of Security Holders (form 8-K)	AQ
23-02-27	OPIANT PHARMACEUTICALS, INC. : Change in Directors or Principal Officers (form 8-K)	AQ
23-02-07	OPIANT PHARMACEUTICALS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)	AQ
23-02-07	Opiant Pharmaceuticals Announces CFIUS Approval for Proposed Acquisition by Indivior PLC	GL

23-02-07	Bolsa de Madrid: Jerome vuelve en la segunda semana
23-02-07	En Direct des Marchés : BNP Paribas, TotalEnergies, L'Oréal, Scor, Casino, CVS, Bayer, Siemens, BP...
23-02-07	Jerome revient en deuxième semaine
22-11-14	MÄRKTE USA/Leichter - Anleger agieren zurückhaltend
22-11-14	MÄRKTE USA/Uneinheitlich - Anleger sind vorsichtig

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
WUXI APPTEC CO., LTD.	+0.06%	+7.20%	+54.04%	+111.13%	74.27B
ARGENX SE	-2.29%	-2.68%	+32.41%	+75.07%	61.21B
WUXI BIOLOGICS (CAYMAN) INC.	+0.28%	+7.27%	+31.74%	+23.80%	27.55B
INSMED INCORPORATED	-2.05%	-1.32%	-18.40%	+352.20%	26.38B
BIONTECH SE	-2.39%	+1.83%	-0.26%	-5.91%	25.34B
GENMAB A/S	+0.57%	+6.60%	+26.25%	-9.37%	20.84B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	-1.47%	+4.46%	-8.09%	+513.33%	14.94B
PHARMAESSENTIA CORPORATION	+1.29%	-2.49%	+163.31%	+333.06%	15.17B
EXELIXIS, INC.	-2.44%	-0.30%	+43.33%	+164.11%	14.41B
Average	-0.94%	+3.20%	+36.04%	+173.05%	31.12B
Weighted average by Cap.	-0.96%	+3.08%	+35.37%	+134.01%

Lightlake Therapeutics Stock OTC Bulletin Board

Stocks

US53224T1051

Biotechnology & Medical Research

Latest news: Lightlake Therapeutics

Analysts' recommendations: Lightlake Therapeutics

Press Releases: Lightlake Therapeutics

News in other languages: Lightlake Therapeutics

Managers and Directors: Lightlake Therapeutics

Bio Therapeutic Drugs

Company Profile

End-of-day quote OTC Bulletin Board
- ^USD	-